Less Risk, More Speed -The New Blueprint For Bioconjugate Development: A Fireside Chat

As bioconjugate programs accelerate, developers are rethinking how to balance speed with risk reduction across increasingly complex modalities such as ADCs and AOCs. Traditional, fragmented development approaches often introduce hidden technical, operational, and transfer risks that surface late—driving delays, cost overruns, or program failure.

This on‑demand fireside chat examines a new development blueprint built around integration rather than handoffs. Anchored in current biologics CDMO market dynamics, the discussion explores how unifying discovery, process development, analytics, and GMP manufacturing can compress timelines while improving predictability. Experts translate market signals into practical strategies for identifying and mitigating risk early, selecting the right partners and technologies, and navigating evolving regulatory expectations for novel modalities. Attendees will gain actionable insights into designing development pathways that eliminate friction, improve execution confidence, and move bioconjugate programs more efficiently from bench to clinic—without sacrificing quality or control.